Jacobs Levy Equity Management Portfolio holdings
Jacobs Levy Equity Management manages U.S. stock portfolios, and its owners Bruce Jacobs and Ken Levy pioneered a research method called disentangling. The firm was founded in 1986, and Jacobs and Levy spent more than three years studying market inefficiencies in U.S. stocks before taking on client money in 1990. Disentangling examines many factors that move stock prices at once, to isolate the separate effect of each, and the firm blends it with behavioral finance theory and human judgment. It runs long-only and long/short portfolios across large and small companies, including versions that hold about 130% or 150% of capital in long positions and 30% or 50% in short ones. Its clients are institutions such as pension plans, endowments, foundations and sovereign wealth funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KLA
KLAC
|
+$325M |
| 2 |
CrowdStrike
CRWD
|
+$225M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$186M |
| 4 |
Sandisk
SNDK
|
+$155M |
| 5 |
Sysco
SYY
|
+$147M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$418M |
| 2 |
ServiceNow
NOW
|
+$262M |
| 3 |
Apple
AAPL
|
+$260M |
| 4 |
Masco
MAS
|
+$163M |
| 5 |
Roku
ROKU
|
+$139M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.14% |
| 2 | Financials | 13.01% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Industrials | 11.2% |
| 5 | Healthcare | 10.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
601
DELISTED
Supernus Pharmaceuticals
SUPN
| $1.93M | 0.01% |
41,593
-1,133
| -3% | -$54.4K |
2025 Q3
3 quarters
|
|
602
Savers
SVV
$1.6B
| $1.93M | 0.01% |
+191,190
| New | +$1.66M |
2026 Q2
0 quarters
|
|
603
Latham Group
SWIM
$973M
| $1.93M | 0.01% |
297,733
-141,396
| -32% | -$794K |
2025 Q4
2 quarters
|
|
604
Owlet
OWLT
$101M
| $1.9M | 0.01% |
330,824
+259,058
| +361% | +$1.37M |
2026 Q1
1 quarter
|
|
605
Donegal Group Class A
DGICA
$713M
| $1.89M | 0.01% |
100,095
-29,132
| -23% | -$506K |
2018 Q4
30 quarters
|
|
606
DELISTED
LXP Industrial Trust
LXP
| $1.87M | 0.01% |
+34,760
| New | +$1.79M |
2026 Q2
0 quarters
|
|
607
National Bank Holdings
NBHC
$1.65B
| $1.87M | 0.01% |
42,063
-5,876
| -12% | -$248K |
2025 Q1
5 quarters
|
|
608
Allegro MicroSystems
ALGM
$5.62B
| $1.87M | 0.01% |
26,833
-281,269
| -91% | -$13.2M |
2026 Q1
1 quarter
|
|
609
Harrow
HROW
$1.13B
| $1.86M | 0.01% |
+43,885
| New | +$1.63M |
2026 Q2
0 quarters
|
|
610
Viridian Therapeutics
VRDN
$3.51B
| $1.86M | 0.01% |
+101,414
| New | +$1.63M |
2026 Q2
0 quarters
|
|
611
Borr Drilling
BORR
$1.06B
| $1.86M | 0.01% |
+449,748
| New | +$2.43M |
2026 Q2
0 quarters
|
|
612
Mistras Group
MG
$644M
| $1.85M | 0.01% |
105,898
-8,579
| -7% | -$153K |
2021 Q2
20 quarters
|
|
613
NOV
NOV
$6.45B
| $1.85M | 0.01% |
+99,536
| New | +$1.98M |
2026 Q2
0 quarters
|
|
614
Highwoods Properties
HIW
$3.43B
| $1.83M | 0.01% |
60,841
+10,547
| +21% | +$273K |
2021 Q1
21 quarters
|
|
615
Sight Sciences
SGHT
$602M
| $1.83M | 0.01% |
338,441
+10,529
| +3% | +$48.5K |
2025 Q4
2 quarters
|
|
616
Titan International
TWI
$329M
| $1.83M | 0.01% |
+237,122
| New | +$1.83M |
2026 Q2
0 quarters
|
|
617
Aveanna Healthcare
AVAH
$2.51B
| $1.82M | 0.01% |
212,197
+925
| +0.4% | +$6.52K |
2024 Q2
8 quarters
|
|
618
Capital City Bank Group
CCBG
$873M
| $1.8M | 0.01% |
36,516
-3,194
| -8% | -$148K |
2017 Q2
36 quarters
|
|
619
G-III Apparel Group
GIII
$1.36B
| $1.79M | 0.01% |
53,031
+29,058
| +121% | +$917K |
2025 Q1
5 quarters
|
|
620
BCB Bancorp
BCBP
$282M
| $1.77M | 0.01% |
164,728
+95,287
| +137% | +$973K |
2020 Q3
23 quarters
|
|
621
Core Scientific
CORZ
$4.68B
| $1.75M | 0.01% |
68,550
-151,118
| -69% | -$3.56M |
2025 Q4
2 quarters
|
|
622
Tompkins Financial
TMP
$1.44B
| $1.75M | 0.01% |
18,530
-4,349
| -19% | -$375K |
2024 Q2
8 quarters
|
|
623
Upstream Bio Inc
UPB
$152M
| $1.75M | 0.01% |
+253,092
| New | +$2.12M |
2026 Q2
0 quarters
|
|
624
DELISTED
BioLife Solutions
BLFS
| $1.75M | 0.01% |
61,852
+50,753
| +457% | +$1.19M |
2025 Q1
5 quarters
|
|
625
Northpointe Bancshares
NPB
$534M
| $1.74M | 0.01% |
90,627
-5,485
| -6% | -$97.9K |
2026 Q1
1 quarter
|
|
Similar funds
Jacobs Levy Equity Management's Q2 2026 Portfolio in Review
As of Q2 2026, Jacobs Levy Equity Management held 1,111 positions worth $27.8B, up 17% from $23.8B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jacobs Levy Equity Management's Q2 2026 filing shows 158 new, 319 increased, 438 reduced and 177 closed positions. Its largest new stake was Sysco: 1,938,184 shares worth $162M. The largest sale was Qualcomm, an estimated $418M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 31% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2026 buy was Sysco: 1,938,184 shares worth $162M.
- Jacobs Levy Equity Management added most to KLA in Q2 2026, an estimated $325M increase.
- Jacobs Levy Equity Management's biggest Q2 2026 reduction was Qualcomm, cutting an estimated $418M.
- Jacobs Levy Equity Management fully exited Roku in Q2 2026, selling an estimated $139M.
- Jacobs Levy Equity Management's ten largest holdings make up 28% of its $27.8B portfolio in Q2 2026.
- Jacobs Levy Equity Management opened 158 new positions and closed 177 in Q2 2026.
- Jacobs Levy Equity Management's portfolio value rose 17% quarter-over-quarter to $27.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.